Gilgamesh Pharmaceuticals alternatives
10 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓| Product | Pricing | Explore |
|---|---|---|
 COMPASS PathwaysBiotech advancing psilocybin therapy for treatment-resistant mental health conditions | See website | Compare |
 ATAI Life SciencesCreating breakthroughs in mental health | See website | Compare |
 MindMedHealthcare & Medical | See website | Compare |
 CybinPioneering next-generation serotonergic agonist therapies for durable mental health improvements | See website | Compare |
| DDelix TherapeuticsRepairing the Brain to Heal the Mind | See website | Compare |
 Seelos TherapeuticsDeveloping therapies for CNS disorders and rare diseases | See website | Compare |
 Beckley PsytechCreating breakthroughs in mental health | See website | Compare |
| SSmall PharmaPharmaceutical development company | See website | Compare |
 LundbeckAdvancing brain health. Transforming lives. | See website | Compare |
 Johnson & JohnsonChanging health for humanity | See website | Compare |
Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Gilgamesh Pharmaceuticals and its alternatives
Users searching for Gilgamesh Pharmaceuticals alternatives are typically exploring other clinical-stage biotechs that develop rapid-acting or plasticity-focused therapies for depression, anxiety, addiction, and schizophrenia. Gilgamesh stands out for its AbbVie-validated NCE platform, short-acting 5-HT2AR agonist, oral low-dissociation NMDAR antagonist, and non-hallucinogenic neuroplastogens. Competing companies range from those advancing psilocybin analogs and ibogaine derivatives to firms focused on muscarinic or glutamatergic mechanisms. Searchers often compare pipeline stage, administration route, hallucinogenic profile, cardiac safety data, partnership validation, and potential for at-home use. This page highlights established players whose approaches overlap or diverge from Gilgamesh's precision chemistry and AI-driven discovery strategy.
Explore the alternatives
1.COMPASS Pathways
Healthcare & MedicalCOMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.
2.ATAI Life Sciences
Healthcare & MedicalATAI invests in and develops multiple mental health compounds including ketamine derivatives and ibogaine analogs. While broader in scope than Gilgamesh, ATAI previously acquired Gilgamesh founders' earlier companies, creating direct lineage overlap in psychedelic and ibogaine chemistry.
3.MindMed
Healthcare & MedicalMindMed advances MM-120, a lysergide d-tartrate for anxiety disorders, and other psychedelic-inspired candidates. Its focus on regulated psychedelic sessions differs from Gilgamesh's emphasis on non-hallucinogenic neuroplastogens and oral NMDAR antagonists suitable for at-home use.
4.Cybin
Healthcare & MedicalCybin develops deuterated tryptamine analogs for depression and anxiety with improved pharmacokinetics. Its shorter-acting candidates share some mechanistic overlap with Gilgamesh's Bretisilocin but lack the same level of big-pharma acquisition validation to date.
- D
5.Delix Therapeutics
Healthcare & MedicalDelix specializes in non-hallucinogenic psychoplastogens targeting structural brain plasticity. Its approach closely mirrors Gilgamesh's AbbVie-partnered neuroplastogen program, though Delix remains independent without equivalent late-stage partnership announcements.
6.Seelos Therapeutics
Healthcare & MedicalSeelos focuses on CNS candidates including SLS-002, an intranasal racemic ketamine for depression and suicidality. Its acute-use formulation differs from Gilgamesh's oral daily-potential NMDAR antagonist aimed at broader outpatient access.
7.Beckley Psytech
Healthcare & MedicalBeckley Psytech develops synthetic 5-MeO-DMT and other short-acting psychedelics for depression. Its emphasis on rapid-onset, shorter-duration compounds parallels Gilgamesh's 5-HT2AR strategy but without the same disclosed big-pharma exit.
- S
8.Small Pharma
Healthcare & MedicalSmall Pharma advances SPL026, a DMT-based short-acting psychedelic for depression. Its pharmacokinetic profile resembles Gilgamesh's Bretisilocin yet remains pre-partnership compared to the AbbVie-validated asset.
9.Lundbeck
Healthcare & MedicalLundbeck develops established psychiatric medications and has explored novel mechanisms for depression. As a large pharma, it offers approved products and global reach unlike Gilgamesh's early-clinical NCE pipeline focused on plasticity mechanisms.
10.Johnson & Johnson
Healthcare & MedicalJ&J markets Spravato (esketamine) nasal spray for depression. Its approved, monitored administration model contrasts with Gilgamesh's pipeline goal of low-dissociation oral agents potentially suitable for at-home psychiatric treatment.
See more comparisons in Healthcare & Medical alternatives.
Questions about Gilgamesh Pharmaceuticals alternatives
What companies develop similar short-acting 5-HT2AR agonists to Gilgamesh's Bretisilocin?
Several biotechs are advancing short-duration psychedelic or 5-HT2AR agonists for depression, though most remain earlier stage or focus on different pharmacokinetic profiles than Gilgamesh's 2-hour treatment window asset now owned by AbbVie.
How does Gilgamesh's oral NMDAR antagonist compare to ketamine alternatives?
Gilgamesh's Blixeprodil offers oral bioavailability and reduced dissociation, aiming to enable at-home administration unlike IV ketamine or esketamine that require clinical monitoring.
Are there non-hallucinogenic neuroplastogen developers besides Gilgamesh and AbbVie?
A small number of companies are pursuing non-hallucinogenic plasticity-promoting compounds, but Gilgamesh's AbbVie partnership provides external validation not shared by most independent programs.
Which firms work on safer ibogaine analogs like Gilgamesh GM-3009?
A handful of biotechs target ibogaine derivatives for OUD and PTSD with improved cardiac safety; Gilgamesh emphasizes structural optimization and maintained efficacy across multiple indications.
What alternatives exist for muscarinic agonists in schizophrenia like Gilgamesh's M1/M4 program?
Larger pharma and smaller biotechs have pursued M1/M4 agonists, but Gilgamesh highlights refined selectivity and reduced peripheral side effects in its oral candidate.
How does Gilgamesh's AI platform differ from other psychedelic drug discovery companies?
Gilgamesh integrates medicinal chemistry expertise with neurocircuitry-focused machine learning for SAR acceleration, validated by an AbbVie acquisition, unlike many peers relying primarily on phenotypic screening.